

Methanogen Hemoaconitase Catalyzes Both Hydrolyase Reactions in Coenzyme B Biosynthesis^{*[S]}

Received for publication, March 18, 2008, and in revised form, August 27, 2008. Published, JBC Papers in Press, September 2, 2008, DOI 10.1074/jbc.M802159200

Randy M. Drevland[‡], Yunhua Jia[§], David R. J. Palmer[§], and David E. Graham^{†¶1}

From the [‡]Department of Chemistry and Biochemistry and the [¶]Institute for Cellular and Molecular Biology, University of Texas at Austin, Austin, Texas 78712 and the [§]Department of Chemistry, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5C9, Canada

Hemoaconitase enzymes catalyze hydrolyase reactions in the α -aminoadipate pathway for lysine biosynthesis or the 2-oxosuberate pathway for methanogenic coenzyme B biosynthesis. Despite the homology of this iron-sulfur protein to aconitase, previously studied hemoaconitases catalyze only the hydration of *cis*-hemoaconitate to form homoisocitrate rather than the complete isomerization of homocitrate to homoisocitrate. The MJ1003 and MJ1271 proteins from the methanogen *Methanocaldococcus jannaschii* formed the first hemoaconitase shown to catalyze both the dehydration of (*R*)-homocitrate to form *cis*-hemoaconitate, and its hydration is shown to produce homoisocitrate. This heterotetrameric enzyme also used the analogous longer chain substrates *cis*-(homo)₂aconitate, *cis*-(homo)₃aconitate, and *cis*-(homo)₄aconitate, all with similar specificities. A combination of the hemoaconitase with the *M. jannaschii* homoisocitrate dehydrogenase catalyzed all of the isomerization and oxidative decarboxylation reactions required to form 2-oxoadipate, 2-oxopimelate, and 2-oxosuberate, completing three iterations of the 2-oxoacid elongation pathway. Methanogenic archaeal hemoaconitases and fungal hemoaconitases evolved in parallel in the aconitase superfamily. The archaeal hemoaconitases share a common ancestor with isopropylmalate isomerases, and both enzymes catalyzed the hydration of the minimal substrate maleate to form *D*-malate. The variation in substrate specificity among these enzymes correlated with the amino acid sequences of a flexible loop in the small subunits.

In the final reaction of methanogenesis, the nickel metalloenzyme methyl-coenzyme M (CoM)² reductase catalyzes the

attack of the coenzyme B (CoB) thiol on the methyl thioether of methyl-CoM, releasing methane and forming a heterodisulfide compound (CoM-S-S-CoB) (1). To reach the deeply buried active site of methyl-CoM reductase, CoB contains a long 7-mercaptoheptanoyl chain with an amide bond to phosphothreonine (2, 3).

Methanogens make the 7-mercaptoheptanoate moiety of CoB from a 2-oxosuberate intermediate, which these cells produce using a series of 2-oxoacid elongation reactions (4). 2-Oxosuberate biosynthesis begins with 2-oxoglutarate from central metabolism (Fig. 1A). The homocitrate synthase enzyme (HCS) catalyzes the aldol-like addition of an acetyl group from acetyl-coenzyme A to 2-oxoglutarate to produce (*R*)-homocitrate. The hemoaconitase enzyme (HACN) is proposed to catalyze the *anti*-elimination of water, forming the *cis*-hemoaconitate intermediate, and its hydration is proposed to produce (2*R*,3*S*)-homoisocitrate. Finally, the NAD⁺-dependent homoisocitrate dehydrogenase enzyme (HICDH) oxidizes and decarboxylates the β -hydroxytricarboxylic acid to produce 2-oxoadipate. Analogous reactions are found in the citric acid (Krebs) cycle, the isopropylmalate pathway to leucine, the pyruvate pathway to 2-oxobutyrate, and the α -aminoadipate pathway (5). In the latter case, some bacteria and fungi use HCS, HACN, and HICDH enzymes to produce 2-oxoadipate for lysine biosynthesis (6). However, methanogens repeat this series of reactions two more times, using 2-oxoadipate to produce 2-oxopimelate and using 2-oxopimelate to produce 2-oxosuberate.

The enzymes in the CoB pathway evolved from leucine biosynthetic proteins that catalyze analogous reactions in the isopropylmalate pathway to 2-oxoisocaproate (Fig. 1B). HCS was identified in the methanogen *Methanocaldococcus jannaschii* as a paralog of isopropylmalate synthase (7). Remarkably, this HCS was reported to convert 2-oxoglutarate and acetyl-CoA to *trans*-hemoaconitate, which was hydrated to form (*S*)-homocitrate. But in analogous reactions, HCS produces (*R*)-homo₂citrate from 2-oxoadipate and (*R*)-homo₃citrate from 2-oxopimelate. Although different acetyl-CoA condensing enzymes are known to have different stereospecificities, each enzyme usually forms only one product (8). The yeast HCS produces only (*R*)-homocitrate (9). (*R*)-Homocitrate is also a key component of the nitrogenase iron-molybdenum cofactor found in many bacteria and some methanogens (10).

Subsequently the *M. jannaschii* HICDH was identified as a paralog of isopropylmalate dehydrogenase (11). This enzyme catalyzes the NAD⁺-dependent oxidation of *threo*-homoisoci-

* This work was supported in part by National Science Foundation Grant MCB-0817903, Petroleum Research Foundation Grant 44382-G4, and Welch Foundation Grant F-1576. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBank™/EBI Data Bank with accession number(s) EU447775.

[S] The on-line version of this article (available at <http://www.jbc.org>) contains supplemental text and supplemental tables.

¹ To whom correspondence should be addressed: 1 University Station A5300, Austin, TX 78712-0165. Fax: 512-471-8696; E-mail: degraham@mail.utexas.edu.

² The abbreviations used are: CoM, coenzyme M; CoB, coenzyme B; HCS, homocitrate synthase; HACN, hemoaconitase; HICDH, homoisocitrate dehydrogenase; IPMI, isopropylmalate isomerase; CHES, 2-(cyclohexylamino)ethanesulfonic acid; TAPS, tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid; HPLC, high pressure liquid chromatography; LC-MS, liquid chromatography-mass spectrometry.




FIGURE 1. Biosynthetic 2-oxoacid elongation pathways. *A*, three enzymes convert 2-oxoglutarate to 2-oxoadipate in the α -aminoacidate pathway and the biosynthesis of the CoB acyl chain. HCS (MJ0503) catalyzes the aldol-type addition of an acetyl group to the *re*-face of 2-oxoglutarate, producing (*R*)-homocitrate. Aconitase or methanogen HACN (MJ1003 and MJ1271) catalyzes the *anti*-elimination of the hydroxyl group and *pro*-*R* hydrogen from homocitrate forming the intermediate *cis*-homoaconitate. All of the HACN enzymes catalyze the *anti*-addition of water to produce (*2R,3S*)-homoisocitrate. Finally, HICDH (MJ1596) catalyzes an oxidative decarboxylation reaction forming 2-oxoadipate. Replacing 2-oxoglutarate with 2-oxoadipate produces 2-oxopimelate, and a third iteration of this pathway produces 2-oxosuberate. *B*, the analogous reactions in leucine biosynthesis in *M. jannaschii* use isopropylmalate synthase (IPMS; MJ1195), IPMI (MJ0499 and MJ1277), and isopropylmalate dehydrogenase (IPMDH; MJ0720). The citramalate synthase (MJ1392) replaces isopropylmalate synthase in isoleucine biosynthesis, using pyruvate to produce (*R*)-citramalate that is converted to 2-oxobutyrate by IPMI and isopropylmalate dehydrogenase (28). The conserved α and β groups and the variable γ groups of *cis*-homoaconitate and isopropylmaleate are labeled for reference.

trate, *threo*-(*homo*)₂isocitrate, and *threo*-(*homo*)₃isocitrate with similar specificity constants. Experiments using cell-free extract from *Methanosarcina thermophila* indicated that (–)-*threo*-homoisocitrate or (*2R,3S*)-homoisocitrate is the relevant diastereomer substrate for methanogen HICDH, similar to bacterial and yeast enzymes (7, 12).

The HACN enzyme in CoB biosynthesis has not yet been identified. It is predicted to differ from the previously characterized HACN enzymes that function in α -aminoacidate pathways for lysine biosynthesis in *Saccharomyces cerevisiae* (13), *Aspergillus nidulans* (14), and the bacterium *Thermus thermophilus* (15). Along with the homologous 2-methyl-*cis*-aconitate hydratase and dimethylmalate dehydratase proteins, those HACN proteins catalyze only half of an aconitase-like reaction (16, 17). The HACN enzymes catalyze the hydration of *cis*-homoaconitate to form homoisocitrate (18). No HACN has been shown to catalyze the dehydration of homocitrate to form *cis*-homoaconitate, but an aconitase enzyme was proposed to catalyze the dehydration of homocitrate in aerobic fungi and *T. thermophilus*. Methanogens have no aconitase, so their HACN must catalyze both half-reactions. Additionally, the methanogen HACN must use tricarboxylate substrates of varying chain length, whereas the HACN proteins from α -aminoacidate pathways need only recognize *cis*-homoaconitate.

Genomes from methanogens that produce CoB contain two copies of genes annotated as encoding large and small subunits of [4Fe-4S]-dependent isopropylmalate isomerases. The large subunit paralogs share more than 50% amino acid sequence identity with each other and more than 40% identity with the *T. thermophilus* HACN subunits. The methanogen small subunits are likewise more similar to each other than to bacterial or

eukaryotic sequences. These genes are scattered around the chromosomes of most methanogens, with little contextual information about gene function. Therefore bioinformatic analysis cannot distinguish the functions of these proteins. We previously identified one combination of *M. jannaschii* proteins (MJ0499 and MJ1277) as the isopropylmalate/citramalate isomerase that is involved in leucine and isoleucine biosyntheses (19).

In this work, the MJ1003 and MJ1271 proteins from *M. jannaschii* formed an active homoaconitase enzyme. HACN activity evolved in parallel in the archaeal and fungal lineages from isopropylmalate isomerase or aconitase ancestors, respectively. Direct assays showed that this reconstituted iron-sulfur enzyme catalyzed the hydration of *cis*-homoaconitate, *cis*-*homo*₂aconitate, *cis*-*homo*₃aconitate, and even *cis*-*homo*₄aconitate with comparable specificity. *cis*-Aconitate

and citraconate were not substrates, although the minimal substrate maleate was hydrated to produce *D*-malate. In a coupled reaction with HICDH, the homoaconitate analogs were converted to their corresponding 2-oxoacids, demonstrating that the homoisocitrate products are substrates for HICDH. In contrast to previously studied HACN proteins, the methanogen enzyme catalyzed both the dehydration of (*R*)-homocitrate to form *cis*-homoaconitate and the subsequent hydration reaction that forms homoisocitrate. HICDH oxidizes and decarboxylates homoisocitrate to make 2-oxoadipate. (*S*)-Homocitrate and *trans*-homoaconitate were inhibitors rather than substrates for HACN, so HACN cannot catalyze all of the predicted dehydratase reactions in the original pathway for CoB biosynthesis.

EXPERIMENTAL PROCEDURES

Chemicals and Reagents—(*R*)-Homocitrate and (*S*)-homocitrate were synthesized through the diastereoselective alkylation of malic acid. (*2R,3S*)-Homocitrate was synthesized from dimethyl *D*-malate (20). *p*-Toluenesulfonic acid was recrystallized from ethyl acetate.

Synthesis of 2-Oxoacids and Homoaconitic Acids—Massoudi *et al.* (21) used the unstable *t*-butyl ester of 2-oxoglutarate in a Wittig-Horner reaction to preferentially produce *cis*-homoaconitate. We have used the stable methyl ester of 2-oxoglutarate **4a** (Sigma) to produce homoaconitate trimethyl ester **5a** (12:1 *cis:trans*) (Fig. 2) (7). *trans*-Homoaconitate trimethyl ester was separated from the *cis*-homoaconitate trimethyl ester by flash chromatography. The purified ester was saponified with sodium hydroxide at 50 °C and extracted from the acidified solution to produce *cis*-homoaconitic acid. The purity of the homoaconitate isomers was established by ¹H NMR. The

Methanogen Homaconitase




FIGURE 2. Chemical synthesis of *cis*-homaconitate methyl esters with different chain lengths in the γ -moiety. The reaction conditions are described under "Experimental Procedures."

assignments of the vinylic proton resonances for each trimethyl ester isomer were confirmed by nuclear Overhauser effect difference spectroscopy. Mass spectra of these compounds were acquired at the University of Texas Mass Spectrometry facility, and ^1H NMR and ^{13}C NMR spectra were acquired at the University of Texas Nuclear Magnetic Resonance facility; these spectra are described in the supplemental materials.

2-Oxadipic Acid—Diethyl glutarate (4.7 g, 25 mmol) was mixed with sodium ethoxide (2.7 g, 40 mmol) in 25 ml of dry diethyl ether at ambient temperature. Diethyl oxalate (4.4 g, 30 mmol) was added dropwise to the stirred solution at ambient temperature. The reaction was quenched with 15 ml of water after 8 h, and the pH was adjusted to neutral with HCl. The triethyl α -oxalyl glutarate **2b** was extracted into diethyl ether and dried over sodium sulfate. The solvent was removed by evaporation under vacuum to afford a yellow oil in 80% yield. Compound **2b** was stirred in 30 ml of 4 M HCl at 80 °C for 6 h to produce 2-oxoadipic acid **3b** (22). The solution was dried by evaporation under vacuum, and 2-oxoadipic acid was crystallized from diethyl ether (34% yield).

2-Oxopimelic Acid—Compound **3c** was prepared by the procedure described for 2-oxoadipic acid, using diethyl adipate instead of diethyl glutarate.

2-Oxosuberlic Acid—Compound **3d** was prepared by the procedure described for 2-oxoadipic acid, using diethyl pimelate instead of diethyl glutarate.

***cis*-(Homo)₂aconitic Acid**—Dimethyl 2-oxoadipate **4b** was prepared by the azeotropic distillation of 2-oxoadipate (1.2 g, 7.2 mmol) in 20 ml of dry chloroform with 10 ml of dry methanol and *p*-toluenesulfonic acid (57 mg, 0.3 mmol) (23). The solvent was removed by evaporation under vacuum, and the product was filtered through a plug of silica (90% yield). Sodium hydride (0.3 g, 8.1 mmol) was dissolved in 10 ml of dry dimethylformamide at 5 °C. Trimethyl phosphonoacetate (Aldrich; 1.2 g, 6.5 mmol) dissolved in 3 ml of dimethylformamide was added dropwise at -5 °C with stirring for 30 min. Compound **4b** (1.2 g, 6.5 mmol) in 3 ml of dimethylformamide was added dropwise, and the mixture was stirred for 1 h. The reaction was quenched with 50 ml of ice water and extracted with diethyl ether. The ether phase was dried with sodium sulfate and concentrated by evaporation under vacuum to produce trimethyl (homo)₂aconitate **5b** in 60% yield as a yellow oil (17:1 *cis:trans* mixture). The isomers were separated by flash chromatography on silica with pentane:ethyl acetate (90:10). Deprotection by saponification and purification of the free acids were carried out as described above to produce *cis*-(homo)₂aconitic acid and *trans*-(homo)₂aconitic acid as yellow oils. Solutions of

acidic substrates were adjusted to pH 7 with KOH before enzymatic analysis.

***cis*-(Homo)₃aconitic Acid**—Trimethyl *cis*-(homo)₃aconitate **5c** was prepared from diethyl adipate **1c**, as described for *cis*-(homo)₂aconitate producing a 10:1 *cis:trans* mixture.

***cis*-(Homo)₄aconitic Acid**—Trimethyl *cis*-(homo)₄aconitic **5d** acid was prepared from diethyl pimelate

1d, producing a 23:1 *cis:trans* mixture.

Cloning and Molecular Biology—Plasmid pT7-MJ1596 (encoding the protein with RefSeq accession number NP_248605.1) was a gift from Huimin Xu and Robert H. White (Virginia Tech) (11). DNA sequencing showed that this cloned gene contained two nucleotide substitutions (C229A and T378C) compared with the MJ1596 sequence reported by the genome sequencing project (24). The C229A transversion resulted in a Q77K amino acid substitution, whereas the second nucleotide difference was silent. Therefore we reamplified the MJ1596 gene from chromosomal DNA of *M. jannaschii* JAL-1 using PCR. DNA amplified using oligonucleotide primers 5MJ1596BN and 3MJ1596B (see supplemental material) was ligated between the NdeI and BamHI sites of vector pET-19b (Novagen) to create vector pDG382, and in the BamHI site of vector pET-43.1c (Novagen) to create vector pDG130. Deletion of the NdeI fragment from pDG130 created vector pDG131. The C229A substitution was also identified in the sequences of these plasmids (the polymorphic gene sequence was deposited into GenBank™ under accession number EU447775). Plasmids were propagated in *Escherichia coli* DH5 α . Sequencing by the DNA facility at the Institute for Cellular and Molecular Biology (University of Texas, Austin) confirmed the cloned DNA sequences. Plasmids for expressing the *M. jannaschii* dehydratase subunits were described previously (19) and are summarized in the supplemental material.

Protein Expression and Purification—The MJ1003 and MJ1271 proteins were coexpressed in an *E. coli* BL21(DE3) (pDG141 pDG163) strain described previously (19). The cells were grown at 37 °C with shaking at 250 rpm until the culture reached an optical density at 600 nm of 0.6–0.8. Expression was then induced by the addition of 50 μM isopropyl-1-thio- β -D-galactopyranoside, and the culture was transferred to a 16 °C water bath and shaken continuously for 15–20 h. The MJ1003 and MJ1271 proteins were purified by heat treatment of the cell lysate, followed by anion exchange chromatography, dialysis, and concentration (19). The protein was further concentrated using a stirred ultrafiltration cell (Amicon) under N₂ with a 10-kDa molecular mass cut-off filter (Pall). The untagged MJ1596 HICDH protein was expressed in an *E. coli* Arctic-Express (DE3)-RIL (pDG131) strain. The cells were grown in medium containing streptomycin (50 $\mu\text{g ml}^{-1}$), tetracycline (50 $\mu\text{g ml}^{-1}$), and gentamycin (50 $\mu\text{g ml}^{-1}$) at 16 °C with shaking at 250 rpm. HICDH protein expression, extraction, purification, and concentration were performed as described for the MJ1003/MJ1271 proteins.

Reconstitution of the Iron-Sulfur Center—In a typical reconstitution reaction, copurified MJ1003 and MJ1271 proteins (1 mg ml⁻¹ apoenzyme) were mixed with Fe(NH₄)₂(SO₄)₂ and sodium sulfide as described previously (19). The reconstitution mixture was stirred under argon until maximum activity was observed (typically 3–4 h). Hydrolyase activity was monitored in a standard assay with 0.2 mM *cis*-homaconitate as described below. A mock reconstitution control consisted of the above mixture without protein.

Determination of Iron-Sulfur Content—The holoenzyme was reconstituted using concentrated MJ1003/MJ1271 apoprotein (2.5 mg ml⁻¹), and then it was desalted using a PD-10 column (GE Healthcare) equilibrated with an anoxic solution of 50 mM Tris/HCl (pH 8.0). Desalting was performed at room temperature in an anaerobic chamber (Coy Laboratory Products) with an atmosphere of N₂:CO₂:H₂ (75:20:5 by volume). Fractions containing the desalted protein were combined, and aliquots were removed for iron and sulfide analyses. Total iron analysis was performed using the colorimetric bathophenanthroline-disulfonate assay with a standard curve prepared from ferric chloride (25). The labile sulfide concentration was determined using the methylene blue assay with the standard addition of sodium sulfide (26). The total protein concentration was determined by the Bradford dye binding method (Thermo-Pierce) using bovine serum albumin as a standard. The standard errors calculated for each assay were propagated to estimate the error associated with each analysis.

Measurement of Hydrolyase Activities—Reactions (1 ml) were conducted in quartz semimicrocells with screw cap septa (Starna) containing 50 mM CHES-KOH (pH 9.0), 200 mM KCl, 20 μg ml⁻¹ holoenzyme, and various substrate concentrations. The sealed quartz cell containing buffer and substrate was degassed under argon for 10 min and equilibrated at 60 °C for 10 min. The reactions were initiated by the addition of holoenzyme, and the decrease in UV absorbance was monitored at 60 °C. Initial rates were measured from the linear portion of the reaction progress curve at 235 nm for *cis*-(homo)₁aconitate ($\epsilon_{235} = 4580 \text{ M}^{-1} \text{ cm}^{-1}$), 235 nm for *cis*-(homo)₂aconitate ($\epsilon_{235} = 4420 \text{ M}^{-1} \text{ cm}^{-1}$), 240 nm for *cis*-(homo)₃aconitate ($\epsilon_{240} = 3180 \text{ M}^{-1} \text{ cm}^{-1}$), and 240 nm and 250 nm for *cis*-(homo)₄aconitate ($\epsilon_{240} = 3140 \text{ M}^{-1} \text{ cm}^{-1}$, $\epsilon_{250} = 1370 \text{ M}^{-1} \text{ cm}^{-1}$). All of the molar absorption coefficients were determined in the reaction buffer at 60 °C. One unit of hydrolyase activity catalyzed the conversion of 1 μmol of substrate to product per min. Steady-state kinetic constants were estimated by nonlinear regression of initial rate data fit to the Michaelis-Menten-Henri equation (19). The inhibitors were screened in direct assays containing buffer, 20 μg ml⁻¹ HACN, and various concentrations of substrate analogs; these reactions were initiated by the anaerobic addition of 100 μM *cis*-homaconitate, and hydrolyase activity was monitored at 240 nm. The stereochemistry of maleate hydration products was determined enzymatically using tartrate dehydrogenase and L-malate dehydrogenase enzymes (19).

Coupled Assay of Hydratase Activity—The hydration of unsaturated intermediates in the forward direction was measured by a coupled reaction with HICDH by monitoring the reduction of NAD⁺ to NADH at 340 nm (15). Reaction mix-

tures containing 50 mM TAPS-KOH (pH 8.5), 50 mM KCl, 5 mM MgCl₂, 20 mM β-mercaptoethanol, 1 mM NAD⁺, and 30 μg ml⁻¹ HICDH were degassed as described above, after which MJ1003/MJ1271 holoenzyme was added to a final concentration of 10 μg ml⁻¹. The reaction mixtures were equilibrated to 60 °C, and the reactions were initiated with 5 μl of substrate. The initial rates were measured using the linear portion of the reaction progress curve. One unit of enzymatic activity catalyzed the reduction of 1 μmol NAD⁺ min⁻¹. The apparent kinetic constants were estimated as described above.

HPLC Analysis of Reaction Products—Standard reactions containing 10 mM *cis*-homaconitate analogs and HACN holoenzyme (40 μg ml⁻¹) were incubated for 20 h at 60 °C. A portion of the reaction product was analyzed by reversed phase HPLC using a Synergi Hydro-RP column (Phenomenex; 250 by 4.6 mm) with a guard column (4 by 3 mm). Chromatography was performed at 35 °C with an isocratic elution with 20 mM potassium phosphate (pH 2.5) and 5% (v/v) acetonitrile in water at a flow rate of 1 ml min⁻¹. Retention factors for standard compounds (*t*₀ = 2.5 min) were 0.4 (homoisocitrate), 1.0 (homocitrate), 1.1 (*cis*-homaconitate), and 2.2 (*cis*-homo₂aconitate). Reaction products from incubations with *cis*-homo₃aconitate and *cis*-homo₄aconitate were analyzed using mobile phase containing buffer and 15% (v/v) acetonitrile in water. The retention factors were 1.5 (*cis*-homo₃aconitate) and 3.5 (*cis*-homo₄aconitate). A photodiode array detector was used to identify analytes; *cis*-homaconitate analogs had absorption maxima near 215 nm, whereas hydroxyacid products absorbed maximally near 205 nm.

LC-MS Analysis of Enzyme Reaction Products—Standard reactions (1 ml) containing 250 μM homoconitate (or analog), and MJ1003/MJ1271 holoenzyme were incubated at 60 °C for 20 h under argon. The reaction mixture was adjusted to pH 1 with HCl and extracted twice with ethyl acetate and once with diethyl ether. The combined organic phases were dried under N₂ at 60 °C. The residue was dissolved in water and analyzed by LC-MS using a Thermo LTQ-XL instrument. The sample was applied to a reversed phase column (Macro Bullet 3 μm 200 Å Magic C18AQ; Michrom Bioresources; 25 × 4 to 1 mm tapered) and eluted with a gradient from 5 to 95% acetonitrile with 0.1% formic acid in water at a flow rate of 0.5 ml min⁻¹. Electrospray ionization mass spectrometry was performed in the negative ion mode.

For the analysis of coupled reaction products, 1 mM NAD⁺ and HICDH were added to the reaction mixture. To form the methoxime derivatives of 2-oxoacid products, the pH was adjusted to 13–14 with sodium hydroxide and 0.25 ml of 10% *O*-methylhydroxylamine hydrochloride was added. The mixtures were incubated at room temperature for 1 h and then adjusted to pH 1 with HCl and saturated with NaCl. The acidic solution was extracted as described above. The concentrated sample was applied to a reversed phase column (Hypersil Gold; Thermo; 50 × 2.1 mm) and eluted with a gradient from 95 to 20% acetonitrile in aqueous 0.1% formic acid at a flow rate of 0.5 ml min⁻¹. Electrospray ionization mass spectrometry was performed in the positive ion mode.

Methanogen Homaconitase




FIGURE 3. HACN catalyzed the hydration of *cis*-unsaturated tricarboxylic acids to produce hydroxyacids. Holoenzyme was incubated with *cis*-homoaconitate analogs for 20 h at 60 °C. The reaction products were separated by reversed phase HPLC with UV absorbance detection in milli-absorbance units (mAU) as described in the text. Substrate peaks (S) were identified by their retention times compared with external standards. Product peaks (P) had absorbance maxima near 205 nm, and they were not observed in control reactions. The unlabeled peaks were also observed in control reactions without enzyme, so they are considered to be contaminants. *A*, incubation with *cis*-homoaconitate (S) produced homocitrate (P) that was confirmed by coinjection with (*R*)-homocitrate. No homoisocitrate was detected in this experiment. *B*, incubation with *cis*-homo₂aconitate produced two product peaks. *C*, incubation with *cis*-homo₃aconitate produced a single product peak. *D*, incubation with *cis*-homo₄aconitate produced two product peaks. The homoaconitate analogs have significantly higher molar absorptivities than their corresponding hydroxy-acids, which preclude direct comparisons of their concentrations by peak area integration.

RESULTS

Hydrolyase Activity of the MJ1003/MJ1271 Proteins—The MJ1003 and MJ1271 proteins were previously coexpressed in *E. coli*, and the apoenzyme was purified to homogeneity by heating and ion exchange chromatography. The subunits associated to form a heterotetramer, similar to the homologous isopropylmalate isomerase complex (19). The MJ1003/MJ1271 apoprotein was mixed with iron(II) and sulfide to reconstitute an air-sensitive iron-sulfur cluster. The resulting holoenzyme contained 5.1 ± 0.2 iron equivalents per MJ1003/MJ1271 dimer and 5.1 ± 0.8 sulfide equivalents, characteristic of a single [4Fe-4S] cluster. Unlike the IPMI enzyme, the MJ1003/MJ1271 complex did not catalyze the hydration of citraconate or the dehydration of citramalate. To test whether this complex had homoconitase activity, *cis*-homoaconitate was synthesized using the Wittig-Horner reaction (Fig. 2). The fully reconstituted MJ1003/MJ1271 holoenzyme catalyzed the hydration of *cis*-homoaconitate with a specific activity of 0.8 unit mg^{-1}

(0.9 s^{-1}) at 60 °C, measured in a continuous spectrophotometric assay. Enzymatic activity was observed between pH 8 and 10, with maximal activity at pH 9. No MgCl_2 was required in this reaction, although activity was highest with 200 mM KCl (activity in the absence of KCl was only 30% of the activity with KCl). In contrast, the MJ1003 and MJ1277 (IPMI small subunit) proteins that also formed a heterotetramer demonstrated no activity with any tested substrate.

Reversed phase HPLC analysis of the MJ1003/MJ1271 reaction products showed a decrease in substrate concentration and the appearance of one new peak corresponding to homocitrate (Fig. 3A). No homoisocitrate was detected. LC-MS analysis of the reaction mixture identified peaks at 205 *m/z* corresponding to the $[\text{M-H}]^-$ ion of homocitrate or homoisocitrate and 187 *m/z* corresponding to the $[\text{M-H}]^-$ ion of homoaconitate. Neither apoenzyme nor a mock reconstitution mixture had hydrolyase activity, confirming that the iron-sulfur cluster in the holoenzyme is essential for activity.

2-Oxosuberate biosynthesis requires three rounds of 2-oxoacid elongation. Therefore the methanogen HACN was predicted to catalyze the isomerization of homocitrate as well as (homo)₂citrate and (homo)₃citrate. As expected, the MJ1003/MJ1271 holoenzyme cata-

lyzed the hydration of *cis*-homoaconitate, *cis*-homo₂aconitate, *cis*-homo₃aconitate, and even the nonphysiological *cis*-homo₄aconitate substrates with similar efficiency (Fig. 3). Surprisingly, no hydration activity was detected in a continuous assay when 0.8 mM *cis*-aconitate was used as a substrate (*i.e.* the rate was less than the limit of detection of 0.029 s^{-1}). Nor was any dehydratase activity observed in reactions containing 5 mM citrate or *threo*-DL-isocitrate.

Steady-state kinetic parameters for HACN were calculated from the initial rates of the hydration reactions for all four substrates (Table 1). The specificity constants for the four substrates are similar, although the turnover number increases for longer γ -carboxylate chain substrates. The Michaelis constant is similar for all three physiologically relevant substrates but is higher for *cis*-homo₄aconitate. Therefore the methanogen HACN does not significantly discriminate between substrates with 2–5 methylene groups in their γ -carboxylate chains.

TABLE 1
Steady-state kinetic parameters for the direct assay of hydrolyase activity

Reactions containing substrate and buffer salts were preincubated at 60 °C before the addition of reconstituted MJ1003/MJ1271 protein to initiate the reaction. Hydrolyase activity was determined by measuring the rate of decrease in UV absorbance caused by the unsaturated substrate, as described under "Experimental Procedures."

Substrate	K_m μM	V_{max} units mg^{-1}	k_{cat} s^{-1}	k_{cat}/K_m $\text{M}^{-1} \text{s}^{-1}$
<i>cis</i> -Homo ₁ aconitate	22 ± 3	0.68 ± 0.03	0.75	3.4 × 10 ⁴
<i>cis</i> -Homo ₂ aconitate	30 ± 5	0.60 ± 0.03	0.66	2.2 × 10 ⁴
<i>cis</i> -Homo ₃ aconitate	36 ± 6	2.2 ± 0.09	2.5	6.8 × 10 ⁴
<i>cis</i> -Homo ₄ aconitate	175 ± 39	5.1 ± 0.3	5.6	3.2 × 10 ⁴
Maleate	330 ± 50	5.5 ± 0.3	6.0	1.8 × 10 ⁴
(<i>R</i>)-Homocitrate ^a	1500 ± 200	0.59 ± 0.03	0.37	2.5 × 10 ²

^a Dehydratase activity was determined by measuring the rate of increase in UV absorbance caused by homoaconitate formation.

Despite its preference for long γ -chain carboxylate substrates, HACN catalyzed the hydration of maleate, a minimal analog of homoaconitate with a hydrogen atom replacing the γ -chain. HACN reactions containing 5 mM maleate produced 5 mM D-malate or (*R*)-2-hydroxysuccinate and no L-malate (<10 μM), determined by enzymatic analysis (19). Therefore the stereochemistry of this hydrolyase reaction is the same as in the physiological reactions, suggesting a similar mode of binding to the active site. The enzyme's K_m for maleate is 10-fold higher than its K_m for physiological substrates (Table 1). However, the turnover number for maleate is high compared with turnovers for the tricarboxylate substrates.

Coupled Activity of HACN with HICDH—The *M. jannaschii* HICDH enzyme was previously shown to catalyze the oxidative decarboxylation of (*-*)-*threo*-homocitrate, (*-*)-*threo*-homo₂isocitrate, and (*-*)-*threo*-homo₃isocitrate (11). To specifically measure the rate of the forward HACN hydration reaction (the conversion of *cis*-homoaconitate to homocitrate), coupled reactions were performed with HACN and excess HICDH monitoring the rate of NADH production. This coupled reaction had maximal activity with 5 mM MgCl₂, 100 mM KCl, 20 mM 2-mercaptoethanol, and a pH of 8.5. The 2-oxoadipate product of these enzymes was identified as the methoxime derivative by LC-MS (Fig. 4). The K_m for *cis*-homoaconitate in this coupled reaction is similar to that measured in the direct assay (Table 2). However, the turnover number increases 2-fold because of the removal of product by HICDH. Comparable results were obtained for *cis*-homo₂aconitate and *cis*-homo₃aconitate substrates, producing 2-oxopimelate and 2-oxosuberate, respectively (Fig. 4, B and C). The *cis*-homo₄aconitate substrate was also efficiently hydrated to produce homo₄isocitrate that HICDH oxidatively decarboxylated to form 2-oxoazolate (Fig. 4D). Although *cis*-homo₄aconitate is probably not physiologically relevant, both the HACN and HICDH enzymes efficiently recognize tricarboxylate substrates with two to five methylene groups in their γ -chains.

Dehydration Reaction and Stereospecificity of HACN—HPLC analysis showed that the primary product of homoaconitate hydration was homocitrate, indicating that the methanogen HACN catalyzed both half-reactions in the isomerization of homocitrate. However, the stereochemistry of homocitrate in this pathway was ambiguous. The partially purified *M. jannaschii* HCS was previously reported to produce (*S*)-homocitrate

from 2-oxoglutarate and acetyl-CoA, but it produced (*R*)-(*homo*)₂citrate from 2-oxoadipate (7). To test which homocitrate enantiomer is a substrate for HACN, we incubated each isomer with HACN and HICDH in coupled assays. (*S*)-Homocitrate was not a substrate for these enzymes (Fig. 5). However, (*R*)-homocitrate was isomerized and oxidatively decarboxylated with a specific activity of 0.3 unit mg⁻¹ (corresponding to a rate of 0.3 s⁻¹ for HACN). In continuous spectrophotometric assays monitoring the formation of homoaconitate, the HACN protein catalyzed the dehydration of (*R*)-homocitrate with a k_{cat} of 0.37 s⁻¹ (Table 1). The rate of dehydration is lower than the rate of *cis*-homoaconitate hydration, as observed for aconitase (27).

Inhibitors of HACN—Product inhibition tests using mixtures of 100 μM *cis*-homoaconitate and 50 μM (*R*)-homocitrate reduced the HACN hydrolyase activity by 50%; no activity was observed in the presence of 100 μM (*S*)-homocitrate. Thus HACN specifically acts on (*R*)-homocitrate, whereas (*S*)-homocitrate inhibits the reaction. In reactions containing 100 μM *cis*-homoaconitate, hydrolyase activity was reduced 50% by the following analogs: 25 μM *cis*-aconitate, 100 μM *trans*-aconitate, and 400 μM *trans*-(*homo*)₃aconitate. No inhibition was observed with citraconate (up to 200 μM).

DISCUSSION

Yeast, some bacteria, and many archaea use a homoaconitase enzyme in the α -amino adipate pathway for lysine biosynthesis. By comparison with the homologous aconitase protein, the HACN enzyme is expected to catalyze the isomerization of homocitrate to homocitrate. Yet the previously studied HACNs catalyzed only the hydration of *cis*-homoaconitate, forming homocitrate. The *M. jannaschii* enzyme described here is the first HACN shown to catalyze both hydrolyase reactions. HPLC analysis showed that this enzyme preferentially converts homoaconitate to homocitrate. Direct assays demonstrated that (*R*)-homocitrate was dehydrated to form homoaconitate. Coupled spectrophotometric assays with HICDH showed that homoaconitate was also converted to homocitrate. The same system was used to show that (*R*)-homocitrate could be converted to 2-oxoadipate, confirming that the methanogen HACN catalyzes the complete isomerization of (*R*)-homocitrate to (2*R*,3*S*)-homocitrate.

The stereospecificity of HACN for (2*R*)-homocitrate and *cis*-homoaconitate analogs shows that it cannot catalyze all of the dehydratase reactions in CoB biosynthesis proposed previously (7). Either additional enzymes are required in that pathway, or 2-oxoacid elongation proceeds through a simpler, evolutionarily conserved pathway using only (*R*)-homocitrate analogs as shown in Fig. 1A (28).

The rate of *M. jannaschii* HACN-catalyzed *cis*-homoaconitate hydration is similar to the rate for the *T. thermophilus* HACN, which has a similar turnover (1.3 s⁻¹) but a lower K_m (8.2 μM) (15). Furthermore, the *M. jannaschii* HACN uses *cis*-homoaconitate analogs with two to five methylene groups in the γ -carboxylate chain, all with similar specificity constants. This broad substrate specificity is surprising given our inability to detect the hydration of *cis*-aconitate, which has a single methylene group. The *M. jannaschii* HACN also catalyzes the

Methanogen Homaconitase




FIGURE 4. **HACN and HICDH hydrated *cis*-homoaconitate analogs and catalyzed their oxidative decarboxylation to produce the corresponding 2-oxoacids.** Methoxime derivatives extracted from the reaction products were analyzed by LC-MS. *A–D* show mass chromatograms for the MH^+ ions of the methoxime-derivatized 2-oxoacids depicted in the *inset*. Similar plots were obtained for the sodium adducts of each acid. *A*, reactions with *cis*-homoaconitate produced 2-oxoadipate indicated by the m/z 190 peak. *B*, reactions containing *cis*-(homo)₂aconitate produced 2-oxopimelate identified by the m/z 204 peak. *C*, reactions containing *cis*-(homo)₃aconitate produced 2-oxosuberate identified by the m/z 218 peak. *D*, reactions containing *cis*-(homo)₄aconitate produced 2-oxoazelate identified by the m/z 232 peak. This derivative formed several noncovalent complexes producing multiple peaks. *E* contains a chromatogram of 2-methoxime dicarboxylic acid standards showing the reconstructed total ion current. The standards included 2-oxoadipic acid (2OA), 2-oxopimelic acid (2OP), and 2-oxosuberic acid (2OS).

TABLE 2
Kinetic parameters for the coupled assay of HACN hydrolyase activity with HICDH

Reactions containing 10 $\mu\text{g ml}^{-1}$ HICDH, 30 $\mu\text{g ml}^{-1}$ HACN holoenzyme, 1 mM NAD^+ , and buffer salts were preincubated at 60 °C before the addition of substrate to initiate the reaction. Hydrolase activity was determined by measuring the rate of increase in UV absorbance at 340 nm caused by the reduction of NAD^+ , as described under "Experimental Procedures."

Substrate	K_m μM	V_{max} units mg^{-1}	k_{cat} s^{-1}	k_{cat}/K_m $\text{M}^{-1} \text{s}^{-1}$
<i>cis</i> -Homo ₁ aconitate	25 ± 3	1.4 ± 0.04	1.5	5.9 × 10 ⁴
<i>cis</i> -Homo ₂ aconitate	20 ± 2	0.93 ± 0.02	1.0	5.0 × 10 ⁴
<i>cis</i> -Homo ₃ aconitate	46 ± 9	4.7 ± 0.3	5.1	1.1 × 10 ⁵
<i>cis</i> -Homo ₄ aconitate	ND ^a	5.8 ^b	ND	ND

^a ND, not determined.

^b Specific activity determined with 0.78 mM *cis*-homo₄aconitate.




FIGURE 5. Hemoaconitase and homoisocitrate dehydrogenase specifically converted (*R*)-homocitrate to 2-oxoadipate in a coupled reaction. The reaction progress curves show the NADH absorbance in reactions containing 0.5 mM (*R*)-homocitrate (solid circles), 0.5 mM (*S*)-homocitrate (open squares), or no substrate (solid squares). A control reaction without hemoaconitase enzyme also showed no NADH production (data not shown).

hydration of the minimal substrate maleate that has no γ -carboxylate chain. This reaction exclusively produces (*R*)-malate, suggesting that the binding modes for the maleate and hemoaconitate substrates are the same. Neither maleate nor the longer chain analogs of *cis*-hemoaconitate have been tested as substrates for the yeast or *T. thermophilus* HACN, so it is unclear whether this broad substrate specificity is unique to the methanogen HACN.

Compared with the rates of hemoaconitate hydration catalyzed by the *M. jannaschii* HACN, the rate of (*R*)-homocitrate dehydration is slow. The same discrepancy was observed in the kinetic analysis of the *M. jannaschii* IPMI, which catalyzed the dehydration of (*R*)-citramalate and 2-isopropylmalate with k_{cat}/K_m values of $2 \times 10^3 \text{ M}^{-1} \text{ s}^{-1}$, more than 2 orders of magnitude lower than the specificity constant for citraconate hydration (19). Future studies may determine the equilibrium constant for this reaction and distinguish the different modes of substrate binding to HACN.

Almost all of the information about the reaction mechanisms of IPMI and HACN proteins has been inferred from aconitase studies (29). Crystal structure models of mitochondrial aconitase with substrate analogs indicate that the protein undergoes long range conformational shifts upon substrate binding (30). The side chains of three residues, Gln⁷², Arg⁵⁸⁰, and Arg⁶⁴⁴ form hydrogen bonds with the γ -carboxylate of isocitrate. The Gln⁷² residue is replaced with His in both IPMI and HACN proteins. The Arg⁶⁴⁴ is universally conserved in the small subunit proteins of IPMI and HACN. Therefore these two residues cannot affect substrate specificity.

Aconitase domain 4 (corresponding to the small subunit proteins of IPMI and HACN) contains a flexible loop with Arg⁵⁸⁰. The sequence of this loop is highly variable and appears to be the best predictor of substrate specificity; archaeal IPMI subunits have a consensus sequence motif of YLV(I/Y/M), whereas archaeal HACN subunits have a consensus sequence of YLRT. The residues in the third and fourth positions of this motif are hydrophobic in IPMI proteins, which could accommodate the hydrophobic γ -chains of their substrates. In contrast the HACN subunits have basic arginine and polar threonine residues that could form an ion pair or hydrogen bond with the γ -carboxylate.

Most crenarchaea have only one HACN/IPMI homolog, even though these microbes apparently use both the isopropylmalate pathway and the α -aminoadipate pathway. Therefore a single isomerase functions in both pathways, suggesting that the ancestral protein could have recognized a broad pool of hydroxyacid substrates. The consensus sequence for the crenarchaeal flexible loop region is YL(K/V)Y, which contains a mixture of residues from both HACN and IPMI motifs. To identify substrate specificity determinants will require cocystal structure models of HACN holoenzyme bound to a substrate analog. Future studies will also replace the amino acids in the HACN motif to change the substrate specificity of the enzyme.

The aconitase crystal structure models show that the same residues bind citrate, *cis*-aconitate, and isocitrate (29). This symmetry makes the inability of the yeast and bacterial HACN proteins to catalyze the dehydration of homocitrate puzzling. The yeast Lys4p HACN homologs have a highly conserved flexible loop consensus sequence of YTYQ, where the tyrosine or glutamine residues could form a hydrogen bond with the γ -carboxylate of *cis*-hemoaconitate. The bacterial HACNs have a conserved loop sequence of YAP(Y/F), suggesting that steric effects or amide backbone interactions with the substrate may be more important than ion pair formation in these proteins. However, changes in the length or conformation of the loop could also affect binding, so additional experiments will be required to determine whether this region is fully modular and responsible for the HACN specificity.

The similarity among 2-oxoacid elongation reactions of the Krebs cycle, leucine biosynthesis, and the α -aminoadipate pathway has been recognized for at least 30 years, along with the proposal that the respective enzymes share common ancestors (5). The homocitrate (*re*)-synthase belongs to the aldolase superfamily. It is related to isopropylmalate synthase and the recently discovered citrate (*re*)-synthase but not to the com-

Methanogen Homaconitase




FIGURE 6. Phylogeny of small subunit IPMI and HACN proteins from archaea. The phylogeny was inferred by the protein maximum likelihood method and rooted using the crenarchaeal IPMI/HACN homologs as an outgroup. The bootstrap values are shown near branches supported by a plurality of 100 trees inferred by the same method. Only the functions of the MJ1277 (IPMI) and MJ1271 (HACN) proteins have been experimentally confirmed, but related proteins predicted to catalyze each reaction are grouped by braces. The numbers in parentheses differentiate the IPMI and HACN paralogs in each species. The full organism names and sequence accession numbers are listed in the supplemental materials. The scale bar indicates 0.1 amino acid changes expected per site.

mon citrate (*si*)-synthase (31), demonstrating convergent evolution. Aconitase, HACN, and IPMI all belong to the same family of [Fe-S] dehydratases. We have shown that *M. jannaschii* HACN and IPMI have relatively broad substrate specificities. The isocitrate, homoisocitrate, and isopropylmalate dehydrogenases belong to another protein superfamily. We have also shown that *M. jannaschii* HICDH and isopropylmalate dehydrogenase recognize diverse dehydratase products with (2*R*,3*S*)-stereocenters. Therefore the invention of an acetyltransferase with new substrate specificity probably spurred the evolution of each 2-oxoacid elongation pathway. This model is consistent with the parallel evolution of HACN activity several times within the dehydratase enzyme family (Fig. 6) and the conserved malease activity.

Acknowledgments—We thank Mehdi Moini and Mark Fountain for assistance with mass spectrometry and Philip Magnus and Ben Shoulders for helpful discussions.

REFERENCES

1. Horng, Y.-C., Becker, D. F., and Ragsdale, S. W. (2001) *Biochemistry* **40**, 12875–12885
2. Noll, K. M., Rinehart, K. L., Jr., Tanner, R. S., and Wolfe, R. S. (1986) *Proc. Natl. Acad. Sci. U. S. A.* **83**, 4238–4242

3. Ermler, U., Grabarse, W., Shima, S., Goubeaud, M., and Thauer, R. K. (1997) *Science* **278**, 1457–1462
4. White, R. H. (1989) *Biochemistry* **28**, 860–865
5. Jensen, R. A. (1976) *Annu. Rev. Microbiol.* **30**, 409–425
6. Xu, H., Andi, B., Qian, J., West, A. H., and Cook, P. F. (2006) *Cell Biochem. Biophys.* **46**, 43–64
7. Howell, D. M., Harich, K., Xu, H., and White, R. H. (1998) *Biochemistry* **37**, 10108–10117
8. Bentley, R. (1970) in *Molecular Asymmetry in Biology* (Bentley, R., ed) pp. 90–163, Academic Press, New York
9. Thomas, U., Kalyanpur, M. G., and Stevens, C. M. (1966) *Biochemistry* **5**, 2513–2516
10. Curatti, L., Hernandez, J. A., Igarashi, R. Y., Soboh, B., Zhao, D., and Rubio, L. M. (2007) *Proc. Natl. Acad. Sci. U. S. A.* **104**, 17626–17631
11. Howell, D. M., Graupner, M., Xu, H., and White, R. H. (2000) *J. Bacteriol.* **182**, 5013–5016
12. Yamamoto, T., Miyazaki, K., and Eguchi, T. (2007) *Bioorg. Med. Chem.* **15**, 1346–1355
13. Strassman, M., and Ceci, L. N. (1966) *J. Biol. Chem.* **241**, 5401–5407
14. Weidner, G., Steffan, B., and Brakhage, A. A. (1997) *Mol. Gen. Genet.* **255**, 237–247
15. Jia, Y., Tomita, T., Yamauchi, K., Nishiyama, M., and Palmer, D. R. J. (2006) *Biochem. J.* **396**, 479–485
16. Grimek, T. L., and Escalante-Semerena, J. C. (2004) *J. Bacteriol.* **186**, 454–462
17. Kollmann-Koch, A., and Eggerer, H. (1984) *Hoppe-Seyler's Z. Physiol. Chem.* **365**, 847–857
18. Bhattacharjee, J. K. (1992) in *The Evolution of Metabolic Function* (Mortlock, R. P., ed) pp. 47–80, CRC Press, Boca Raton, FL
19. Drevland, R. M., Waheed, A., and Graham, D. E. (2007) *J. Bacteriol.* **189**, 4391–4400
20. Ma, G., and Palmer, D. R. J. (2000) *Tetrahedron Lett.* **41**, 9209–9212
21. Massoudi, H. H., Cantacuzene, D., Wakselman, C., and de la Tour, C. B. (1983) *Synthesis* **12**, 1010–1012
22. Nelson, R. B., and Gribble, G. W. (1973) *Org. Prep. Proc. Int.* **5**, 55–58
23. Clive, D. L. J., Coltart, D. M., and Zhou, Y. (1999) *J. Org. Chem.* **64**, 1447–1454
24. Bult, C. J., White, O., Olsen, G. J., Zhou, L., Fleischmann, R. D., Sutton, G. G., Blake, J. A., FitzGerald, L. M., Clayton, R. A., Gocayne, J. D., Kerlavage, A. R., Dougherty, B. A., Tomb, J.-F., Adams, M. D., Reich, C. I., Overbeek, R., Kirkness, E. F., Weinstock, K. G., Merrick, J. M., Glodek, A., Scott, J. L., Geoghagen, N. S. M., Smith, H. O., Woese, C. R., and Venter, J. C. (1996) *Science* **273**, 1017–1140
25. Wu, S.-p., Wu, G., Surerus, K. K., and Cowan, J. A. (2002) *Biochemistry* **41**, 8876–8885
26. Beinert, H. (1983) *Anal. Biochem.* **131**, 373–378
27. Henson, C. P., and Cleland, W. W. (1967) *J. Biol. Chem.* **242**, 3833–3838
28. Graham, D. E., and White, R. H. (2002) *Nat. Prod. Rep.* **19**, 133–147
29. Beinert, H., Kennedy, M. C., and Stout, C. D. (1996) *Chem. Rev.* **96**, 2335–2374
30. Lauble, H., Kennedy, M. C., Beinert, H., and Stout, C. D. (1992) *Biochemistry* **31**, 2735–2748
31. Li, F., Hagemeyer, C. H., Seedorf, H., Gottschalk, G., and Thauer, R. K. (2007) *J. Bacteriol.* **189**, 4299–4304